ArticleCancer2018

A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.

Christos Fountzilas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.